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The blood-brain barrier (BBB) is a diffusion barrier that has an important role in
maintaining a precisely regulated microenvironment protecting the neural tissue from
infectious agents and toxins in the circulating system. Compromised BBB integrity
plays a major role in the pathogenesis of retroviral associated neurological diseases.
Human Immunodeficiency Virus (HIV) infection in the Central Nervous System (CNS)
is an early event even before the serodiagnosis for HIV positivity or the initiation
of antiretroviral therapy (ART), resulting in neurological complications in many of the
infected patients. Macrophages, microglia and astrocytes (in low levels) are the most
productively/latently infected cell types within the CNS. In this brief review, we have
discussed about the effect of HIV infection and viral proteins on the integrity and function
of BBB, which may contribute to the progression of HIV associated neurocognitive
disorders.
Keywords: HIV, gp120, Tat, Nef, Vpr, blood-brain barrier, neurocognitive disorders
Introduction
The brain functions within a well-controlled environment that is quite distinct from
other parts of the body. Any changes in the environment of the brain result in
reversible or irreversible and fatal or non-fatal conditions. The blood-brain barrier
(BBB) is a diffusion barrier essential for the normal function of the central nervous
system (CNS). Ballabh et al. (2004) and Weiss et al. (2009) have overviewed the
structure and functional role of the BBB in brain homeostasis. The BBB is a
protective, selectively permeable barrier that protects the brain from foreign substances
(infectious agents and neurotoxic substances) in blood that might damage the brain.
It also protects the brain from many circulating hormones and neurotransmitters
in the peripheral system of the body. Apart from providing a secure environment
for neural network in the brain, it acts as a regulator of energy metabolites,
specific ion channels and transporters. For example, water, glucose, amino acids and
some lipid soluble molecules that are essential for neuronal growth and function
will pass through the BBB by passive diffusion and selective transport mechanisms,
while preventing the entry of lipophilic and potential neurotoxic substances. The BBB
endothelial cells are different from the ones in the rest of the body since they lack
fenestrations, have more broad tight junctions (TJs), and a scant pinocytic vesicular
transport. In addition, the BBB is made of the capillary basement membrane (BM),
pericytes (PCs) embedded within the BM and astrocyte end-feet enclosing the vessels (Figure 1).
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Infections of the CNS are very common and cause
high morbidity and mortality in children as well as in
immunocompromised persons. The most common organisms
involved in CNS infections are Streptococcus pneumoniae,
Hemophilus influenzae type B, Neisseria meningitides, Listeria
monocytogenes, and Human Immunodeficiency Virus (HIV)
type-1. HIV-1 exhibits extensive genetic variation worldwide and
is categorized into three groups (M, O, and N) and genetically
into nine different subtypes (A–K). Of these, clades B and C
represent the majority (>86%) of circulating HIV-1 variants
(Osmanov et al., 2002). While HIV-1 clade B is predominant
in North America, Western Europe, and Australia; clade C is
common in Southern and East Africa, India and Nepal and
is responsible for around half of all HIV infections. HIV is
a neurotropic virus causing inflammatory and neurotoxic host
responses. Severe neurological disorders caused by HIV are
collectively known as HIV-associated neurocognitive disorders
(HAND). HAND is characterized by the development of
cognitive, motor and/or behavioral impairments and consists of
several clinical forms ranging from asymptomatic neurocognitive
impairment (ANI), minor neurocognitive disorder (MND) to
the most severe HIV-associated dementia (HAD) (McArthur
and Brew, 2010). HIV-encephalitis (HIVE) is the main cause
of HAND and the most common neurologic disorder of the
brain in HIV-1 infection. Disruption of the BBB caused by
HIV-1 plays an important role in AIDS neuropathogenesis
(Persidsky and Gendelman, 2003; Toborek et al., 2005),
but the exact mechanisms of HIV entry into the brain
across the BBB remain unclear. Numerous studies have used
animal models as well as in vitro experimental studies to
understand the mechanisms of HIV-1 introduction into the
CNS through the BBB (González-Scarano and Martín-García,
2005).
The commonly recognized model, with the most valid
evidence, is the ‘‘Trojan Horse hypothesis’’ (Peluso et al., 1985).
Based on this model, HIV-1 and other lentiviruses cross the
CNS as a passenger in cells trafficking to the brain. HIV-1
infects several CD4+ (cluster of differentiation 4) cells, such
as T cells and monocytes. These cells circulate in the blood,
cross the BBB and propagate the infection within the CNS
(Figure 1). It has also been shown that macrophage tropism
is a prerequisite for the neurotropism of HIV. This study
was done using molecularly cloned simian immunodeficiency
virus in macaques (SIVmac) 239, which is a lymphocyte virus
rather than macrophagetropic. This study showed that after
intracerebral (i.c.) inoculations, the infection propagated in
lymphoid organs and bone marrow, and did not infect the
brain directly. This resulted in severe neurological disease and
classical neuropathological injuries (Sharma et al., 1992). Other
proposed mechanisms include direct infection of cells that
comprise the BBB, endothelial cells and astrocytes, and transfer
via these cells from the periphery to the CNS (Mankowski
et al., 1994; Argyris et al., 2003; Bobardt et al., 2004) or
direct extracellular movement of the virus across a disrupted
BBB. Even though these mechanisms are important to take in
consideration, they are less well characterized, and are possible
minor contributors to CNS infection. HIV replicates in brain
microglia as well as macrophages, producing inflammatory
and neurotoxic host responses (Anthony et al., 2005). It has
been demonstrated that HIV-1 infection of human brain PCs
and disruption of BBB integrity might also contribute to
the progression of HIV-1 induced CNS damage (Nakagawa
et al., 2012). HIV may cause cognitive, behavioral, and motor
difficulties in 40–60% of infected individuals even in the current
antiretroviral therapy (ART) era (Anthony et al., 2005). These
difficulties may range in severity from very mild to severe and
disabling.
Since the BBB does not allow easy transfer of any foreign
molecules, treatments of these infections become more difficult
(Guduru et al., 2013; Pilakka-Kanthikeel et al., 2013; Ding
et al., 2014; Jayant et al., 2015). The BBB integrity is disrupted
throughout the pathogenesis of neuroAIDS by mechanisms that
comprise higher transmigration of HIV-infected monocytes,
decline in BBB TJ protein expression, and apoptosis (Dallasta
et al., 1999; Eugenin et al., 2006). The aim of this review is to
update the effect of HIV infection and role of different HIV
proteins in BBB integrity and functions.
HIV Infection of CNS Cells and Effect on
BBB Permeability
The BBB composition consists of highly specialized
microvascular endothelial cells that are found on the basal
lamina. Astrocyte end feet interaction with the basal lamina
and their proximity to endothelial cells and accessory cells
including microglia, perivascular macrophages and PCs has
been observed (Abbott, 2002; Ballabh et al., 2004). The processes
of astrocytes end feet surround the brain capillaries, giving
important factors for the maintenance and development
of the BBB (Goldstein, 1988; Risau and Wolburg, 1990;
Risau, 1991; Hayashi et al., 1997). These astrocytes end feet
aid in the regulation of the BBB physiology using soluble
factors (Rubin and Staddon, 1999; Hawkins and Davis,
2005; Iadecola and Nedergaard, 2007), direct intercellular
communication through gap junction (GJ) channels and by
connexin/pannexin hemichannels found on cells surface,
in which the cytoplasm and the extracellular environment
join together. GJs are a combination of channels that allow
the interchange of particles up to 1.2 kDa among the
cytoplasm of nearby cells (Saez et al., 2003). Every channel
is composed of the cutting of two hemichannels, which are
found in opposing cell membranes; each hemichannel is
a group of six connexins (Cxs). GJ connection decreases
during pathological settings, such as inflammation and viral
infections (Danave et al., 1994; Faccini et al., 1996; Rouach
et al., 2002; Kielian and Esen, 2004; Knabb et al., 2007). Due
to the expression of connexin43 (Cx43) and functional GJ
communication among astrocytes, toxic signals produced in
the HIV infected astrocytes extent to the nearby uninfected
astrocytes (Eugenin and Berman, 2007). Cell-to-cell interaction
has been shown to be an effective transmission pathway of
HIV from T lymphocytes to astrocytes. This was observed
through a dynamic binding process of filopodial extensions
from either cell type, developing virological synapses. These
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FIGURE 1 | The blood-brain barrier (BBB) with HIV infected cells: Schematic representation of structure of the blood brain barrier and HIV infected
cells in blood and CNS.
interactions could be inhibited by anti-C-X-C chemokine
receptor type 4 (CXCR4) antibody and its antagonist (Ma et al.,
2015).
In the brain, perivascular macrophages and microglia are the
productively infected cell types by HIV in vivo (Wiley et al.,
1986; Cosenza et al., 2002). Studies have shown that SIV-infected
macrophages lower electrical resistance of the endothelial cell
monolayer after adding them to the parenchymal face of an
inverted BBB model (Sansing et al., 2012). Using an in vitro BBB
model, HIV infection of leukocytes reported to increase their
transmigration across the BBB in response to the chemokine
ligand 2 (CCL2) as a result of increased permeability, reduced
TJ proteins such as zonula occludens-1 (ZO-1), claudin-1,
and occludin in the BBB cells, and up-regulation of matrix
metalloproteinases (MMP)-2 and MMP9 (Eugenin et al., 2006).
Nevertheless, astrocytes have also been reported to get infected by
HIV in low levels (Wiley et al., 1986; Conant et al., 1994; Nuovo
et al., 1994; Tornatore et al., 1994; Bagasra et al., 1996; Takahashi
et al., 1996; Ohagen et al., 1999; Eugenin and Berman, 2007;
Churchill et al., 2009; Atluri et al., 2013). C-C chemokine receptor
type 5 (CCR5) and CXCR4 are functional HIV co-receptors
observed in astrocytes, which assist in infection (Klein et al.,
1999). Even though a small amount of infected astrocytes were
observed in vitro (4.7 ± 2.8% of the total astrocytes in the
culture) as well as a low HIV production, GJ channels intensify
and extent toxic signals to the adjacent cells in the culture that
were not infected (Eugenin and Berman, 2007). It has been
observed that this small population of infected astrocytes, with
significant viral production, is able to cause intensemodifications
in the physiology of the BBB in vitro as well as in vivo
when SIV-infected macaques brain sections were used (Eugenin
et al., 2011). In addition, HIV infection of human astrocytes
was demonstrated to induce increased expression of dickkopf-1
protein (DKK1; a soluble inhibitor of Wnt signaling) by a Cx43
hemichannel HC-dependent mechanism, which is associated
with the brain pathogenesis found in HIVE patients. Even in
the absence of HIV infection, co-cultured primary neurons and
astrocytes in the presence of increasing concentrations of DKK1
resulted in neuronal damage (Orellana et al., 2014). One of
the major notable pathological features in neuroAIDS has been
reported to be the disruption of the BBB (Dallasta et al., 1999;
Luabeya et al., 2000; Eugenin et al., 2006). To see the effect
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of HIV infected astrocytes on BBB permeability, a BBB was
constructed using infected/uninfected astrocytes and Evans Blue
(EB) conjugated albumin permeability test was used. In the
BBB with HIV infected astrocytes, high permeability, endothelial
apoptosis, erroneous astrocyte end processes and abnormal
interactions with the endothelium were reported (Eugenin et al.,
2011).
Effect of HIV Proteins on BBB Permeability
and Function
It is well known that HIV-1 genome encodes Gag, Pol, and Env
polyproteins which are subsequently proteolyzed into individual
proteins. The four Gag proteins, matrix, capsid, nucleocapsid
and p6 proteins and the two Env proteins, surface gp120,
transmembrane gp41 are structural proteins that makeup the
core and outer membrane of the virion. The three Pol proteins
protease, reverse transcriptase, and integrase are encapsulated
within the particle and play a major role in viral replication
(Frankel and Young, 1998).
Effect of HIV gp120 Protein on BBB
Permeability
Gp120 is a potent neurotoxin, causing neurotoxicity even
in pico molar concentration and has been detected in the
serum of HIV-infected patients (Ellaurie et al., 1990). Viral
entry into the host cell is initiated by binding of the gp120
located on the viral membrane surface to a specific cell specific
receptor (especially CD4) (Frankel and Young, 1998). HIV-
1 co-receptors CCR5 and CXCR4 are expressed by human
brain microvascular endothelial cells (hBMVECs). When these
cells were exposed to HIV gp120 protein, derived from HIV
infected lymphocytes or macrophage-tropic viruses, endothelial
monolayer permeability and monocyte migration in in vitro
models were increased (Kanmogne et al., 2007). In an in
vitro setup of brain endothelial cells obtained from gp120
transgenic mice and non-transgenic mice, increased permeability
of endothelial cell layer exposed to the serum containing gp120
was reported and the permeability was restored by using the anti-
gp120 antibody demonstrating the effect of circulating gp120
on BBB permeability (Cioni and Annunziata, 2002). The gp120
also produced down-regulation of TJ proteins, such as ZO-
1, ZO-2, and occludin, functions in cross-linking which led
to the increased permeability of the endothelial mono layer
(Kanmogne et al., 2005). It has been shown that TJ disturbance
among hBMVECs is mediated by activating the focal adhesion
kinase (FAK) through phosphorylation at tyrosine (TYR)-397.
Nevertheless, inhibiting FAK activation was enough to avoid
disturbance of TJ (Ivey et al., 2009).
It has also been reported that gp-120 proteins increased
the expression of MMPs 2 and 9 and subsequently Claudin-
5 and laminin, which are key targets of these MMPs were
reduced. In addition, even acute exposure of gp120 intensifies
lipid peroxidation in neurons as well as in the vascular
endothelium. Further, administration of antioxidants could
be able to protect the BBB from the gp120-induced BBB
damage (Louboutin et al., 2010). Moreover, studies have
shown that lymphatic hyperpermeability was induced by
gp120 through the functional disruption of Robo4, a novel
regulator of endothelial permeability. HIV-1 gp120 caused
integrin α5β1 phosphorylation and fibronectin expression,
which led to their association with Robo4 through its
fibronectin type III domains (Zhang et al., 2012). On the
other hand, when an active N-terminus portion of Slit2,
a Robo4 agonist, was used for pretreatment, lymphatic
endothelial cells demonstrated to be protected against HIV-1
gp120-induced hyperpermeability. This happened through
the inhibition of c-Src kinase activation (Zhang et al.,
2012).
CCR5 antibodies and inhibitors of myosin light chain kinase
or protein kinase C (PKC) were able to block and reduce the
permeability of BBB in vitro as well as monocyte migration
due to the exposure of gp120. In addition, CCR5 antibody
and CXCR4 antagonist prevented and partially blocked the
gp120 induced release of intracellular calcium, respectively.
Some junctional proteins, such as claudin-1 and claudin-5
did not show any change or effect. Specific PKC inhibitors,
acting at the calcium release and adenosine triphosphate (ATP)-
binding site, prevented intensification in BBB permeability and
blocked gp120-induced PKC (PKC activation). Additionally,
the integrity of the BBB was restored after the removal of
gp120 (Kanmogne et al., 2007). Studies have also shown
that hBMVECs treated with proteasome inhibitor, lactacystin,
reduced the deprivation of ZO-1 and ZO-1. Up-regulation
of a scaffold protein, 14-3-3τ, which is a negative regulator
of TJ proteins has also been reported in the presence of
gp120. These results indicate that TJ proteins were directed by
gp120 for deprivation through the proteasome, portraying a
novel molecular mechanism for the BBB breakdown by gp120
(Nakamuta et al., 2008).
Furthermore, when immortalized endothelial cell line from
rat brain capillaries (RBE4) were treated with gp120 and
Tat, levels of glutathione peroxidase (GPx), intracellular
reduced glutathione (GSH), and glutathione reductase (GR)
content were decreased while levels of malondialdehyde (MDA)
were increased. Reduced glutathione and oxidized glutathione
(GSH/GSSG) ratio was taken in consideration as an oxidative
stress indicator, in which the ratio was reduced in both
gp120 and Tat exposed RBE4 cells (Price et al., 2005). These
outcomes demonstrated that cellular expression of gp120
increased MMPs and reduced vascular TJ proteins, leading to
a disturbance of the BBB permeability. This confirms that HIV
gp120 induces oxidative damage and production of reactive
oxygen species (ROS), which lead to the alteration of the BBB
integrity (Louboutin et al., 2010). These changes increase the
trafficking of toxic humoral factors and HIV infected cells
into the CNS, which contribute to the pathogenesis of severe
forms of HIV associated neurocognitive disorders i.e., HAD
(Kanmogne et al., 2005). In addition, it was demonstrated
that, up-regulation of cannabinoid receptor 2 (CB2R) levels
in brain endothelium during neuroinflammation is able to
increase the quantity of TJ protein found in membrane fractions.
Further, in lipopolysaccharide administered in vivo mouse
Frontiers in Cellular Neuroscience | www.frontiersin.org 4 June 2015 | Volume 9 | Article 212
Atluri et al. Blood-brain barrier integrity in HIV infection
model, the role of CB2R in attenuation of inflammatory
response and in preventing BBB leakiness was confirmed by
using CB2R agonists (Ramirez et al., 2012). In an in vivo
experimental male Wistar rat model, up regulation of IL-
1β and inducible nitric oxide synthase (iNOS) transcripts
were also observed in the presence of gp120. However, anti-
inflammatory compounds, such as minocycline, chloroquine and
simvastatin, are able to decrease neuroinflammation induced
by gp120. This effect has been reported to be mediated by the
interaction with the mitogen-activated protein kinase (MAPK)
signaling pathway (Ashraf et al., 2014). In an in vivo rat
caudate-putamen gp120 and EB intravenous injection study,
gp120 induced extravasation of the EB (Louboutin and Strayer,
2012). This information reveals that HIV gp120 proteins affect
the functional as well as molecular properties of the BBB.
Effect of HIV Trans-Activator of
Transcription (Tat) Protein on BBB
Permeability
Despite the presence of different cellular transcription factors
like nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-kB), specificity protein 1 (Sp1) and TATA-binding
protein (TBP), which help in transcriptional initiation from the
integrated provirus, Tat is required to enhance the processivity
of transcribing polymerases. Tat is also able to increase the
rate of transcription initiation and production of viral mRNAs
more than 100 fold, consequently required for viral replication
(Frankel and Young, 1998). HIV Tat has also shown to have
effects on BBB integrity mediated by oxidative stress (Price
et al., 2005; Pu et al., 2005). Although studies have shown that
Tat affects TJ protein expression, detailed mechanisms have
not been clearly described yet. HBMVECs that were exposed
to HIV Tat revealed a decline in occludin mRNA and protein
levels via RhoA/ROCK signaling pathway. However, p160-Rho-
associated coiled kinase (ROCK) inhibitor Y-27632 and RhoA
inhibitor C3 exoenzyme moderately diminished the effect (Xu
et al., 2012).
Additionally, Rho signaling in HBMVECs was demonstrated
to have a significant role in monocyte migration through the
BBB and in TJ assembly. Rho activation negatively regulates
the TJ assembly and studies have shown that monocyte
migration was decreased by 84% when dominant-negative
Rho K-transfected BMVECs were utilized in BBB models
(Persidsky et al., 2006). Exposure to Tat results in Rho
activation, TJ integrity disruption and enhanced monocyte
migration across the BBB which has been shown during the
HIV infection as well (Persidsky et al., 2006; Zhong et al.,
2012). Activated monocytes demonstrated higher quantities of
lysosomes, philopodia, vesicular Golgi complexes as well as
augmented expressed levels of proinflammatory cytokines, such
as IL-6, IL-10, and TNF-alpha which further affect the BBB
integrity (Persidsky et al., 1997).
CCL2/MCP-1 reported to induce chemotaxis of human
microglia, indicating that uninfected cells can be induced to
migrate areas of active infection or BBB disruption where
CCL2/MCP-1 is released in response to Tat (Eugenin et al.,
2005). Furthermore, Tat induced the expression of MMP-9
and the concentration of soluble occludin in cells’ supernatants
and the paracellular permeability of hBMVEC treated with
Tat decreased due to RNA interference targeting MMP-9.
These data explain how Tat disturbs the integrity of BBB
by diminishing occludin production and cleaving occludin
through MMP-9 (Xu et al., 2012). Moreover, studies in
hCMEC/D3 cell line treated with Tat demonstrated a down
regulation in ZO-1 total levels, but an up regulation of ZO-1
expression in the nuclei. Nevertheless, when the Rho cascade
was inhibited by infecting Adenovirus expressing exoenzyme
C3 transferase (C3 Adenovirus), ZO-1 up regulation in the
nucei and CREB activation induced by Tat were prevented.
The depletion of CREB by infecting cells with certain shRNA
lentiviral particles, attenuated Tat induced nuclear targeting
of ZO-1, Rho signaling and transendothelial migration of
monocytic cells. The CREB level depletion also inhibited Tat
induced hyperpermeability of endothelial and BBB (Zhong
et al., 2012). Particularly, peroxisome proliferator-activated
receptor (PPAR)α or PPARγ up-regulation attenuated HIV-
mediated dysregulation of TJ proteins. These outcomes were
also associated with the down regulation of MMP and
protease activities. These studies clearly observed that HIV-
induced down regulation of junctional adhesion molecule-A
(JAM)-A and ZO-1 were restored by inhibiting MMP and
proteasome activity by using the PPARγ agonists (15d-PGJ2
and troglitazone). This data indicated a novel mechanism
of PPAR-induced defenses against HIV-induced disturbance
of brain endothelial cells (Huang et al., 2009; Zhong et al.,
2012). In the same way, Tat-induced synaptic loss and
cell death were blocked by creatine and protected against
Tat induced ATP depletion, proposing that it may be a
convenient adjunctive therapy for HAND (Stevens et al.,
2014).
In addition, in vivo experiments have shown that Tat
crossed the BBB through a nonsaturable mechanism with a
unidirectional inflow level of 0.490 µl/g/min. Approximately,
0.126% of an intravenous dose of Tat goes into each gram of
brain (Banks et al., 2005). The uptake rate for Tat is analogous
to the one at which several active proteins cross the BBB, such
as IL-1 and TNF-alpha (Banks et al., 1991; Gutierrez et al.,
1993). Tat is able to bind to different cell surface receptors,
such as vascular endothelial cell growth factor receptor-2 on
brain endothelial cells, low density lipoprotein receptor-related
protein on brain neurons and the Fik-1KDR receptor on
peripheral vascular endothelial cells. Definitely, it was observed
that Tat crossed without disturbing the BBB, since radioactively
labeled albumin that was injected simultaneously did not
cross the BBB. These studies confirm that specific regions
of the brain, such as the occipital cortex, hypothalamus and
hippocampus are more permeable to Tat. Therefore, it was
shown that Tat ended up crossing the BBB bidirectionally.
Studies found that over 90% of the Tat taken up by the brain
passed through the full width of the capillary wall (Banks
et al., 1991, 2005; Albini et al., 1996; Liu et al., 2000; Khan
et al., 2003). In addition, Tat may be crossing the BBB in
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the same way that HIV-1 gp120 does, through adsorptive
endocytosis. The permeability observed in these studies, can
give an insight and proposal of the mechanism involved by
which the production of Tat on one side of the BBB could
disturb immune or neural functions on the other side (Banks
et al., 2005). Recently one study has shown that HIV-1 uses a
uniform distribution of mannose-6 phosphate receptor (M6PR)
to cross the BBB, using a transcytotic pathway (Dohgu et al.,
2012).
HIV-1 Tat C protein has also been observed to increase
intracellular ROS level and induce nicotinamide adenine
dinucleotide phosphate-oxidase 2 (NOX2) andNOX4 expression
levels in hBMVECs. An increased β-catenin and vascular
endothelial-cadherin TYR phosphorylation by activation of
Redox-sensitive kinase proline-rich tyrosine kinase 2 (PYK2),
led to the disruption of junctional assembly. Phosphorylation
of junctional proteins in hBMVECs caused disturbance in
junctional complexes and endothelial permeability (Mishra and
Singh, 2014).
HIV-1 Negative Regulatory Factor (Nef)
Protein on BBB Permeability
HIV-1 Nef protein has been shown to promote pathogenesis
of HIV infection by facilitating the down-regulation of CD4
and through signal transduction interference by binding to
cellular protein kinases and enhance the virus replication in
the infected host (Frankel and Young, 1998; Abraham and
Fackler, 2012). In animal models, MMP-9 activity was identified
in CSF samples that were intracisternally injected with Nef.
However, these results were not detected when heat-inactivated
Nef, gp160, or gp120 were injected. This HIV-1 protein was
observed to induce a rupturing of the BBB, which could be
inhibited by pretreatment with MMP inhibitor batimastat. In
vitro experiments showed that Nef induced MMP-9 activity in
a lower level in isolated PBMCs and in the murine macrophage
cell line RAW 264.7. However, these results were not observed
in astroglial, neuronal or endothelial cell lines. These data point
out that Nef is able to induce disturbance or disruption in
the BBB, most likely via the induction of MMP (Sporer et al.,
2000).
Nef has also demonstrated to play amajor role in the depletion
of T cells through the stimulation of apoptosis in bystander cells.
Treatment with low levels of extracellular Nef concentrations,
showed a moderate quantity of programmed cell death. On the
other hand, when high levels of extracellular Nef concentrations
were used, a significant induction of apoptosis was observed.
Results also showed an up-regulation of proapoptotic genes,
such as caspase-6, -8, -9, and -10 along with tumor necrosis
factor receptor 12 (TNFR 12), tumor proteins p53 and p73,
Death-associated protein 6 (DAXX), MAPK/extracellular signal-
regulated kinase (ERK) 3, and MAPK 7 (Acheampong et al.,
2005). Studies have also shown the suppression of B-cell help
through HIV-1 infected T lymphocytes as well as a decrease
in parenchymal lymphocyte motility, might contribute to the
cell-associated virus spread of HIV infection in surrounding
cells. These suggest not only that HIV-1 Nef induces apoptosis
in hBMVECs, but that it may use different pathways in inducing
AIDS pathogenesis (Stolp et al., 2012).
HIV-1 Viral Protein R (Vpr) in BBB
Permeability
HIV-1 Viral Protein R (Vpr) is a very versatile or adaptable
protein in HIV-1 life cycle that participate in cell cycle
arrest at the G2 phase, transport of the pre-integration
complex into the nucleus and activation of HIV-1 long-
terminal repeat (Heinzinger et al., 1994; He et al., 1995;
Vanitharani et al., 2001). According to some studies, decrease of
plasminogen activator inhibitor-1 (PAI-1) protein in astrocytes
exposed to Vpr could give harmful effects by reducing BBB
integrity and tightness. A balanced production of this protein
is vital for endothelial cells in the CNS. In exposure to
primary human fetal astrocytes, extracellular Vpr has shown
to contribute to an increased level in the permeability of the
BBB along with an increased recruitment of cells through
dysregulation of the astrocyte compartment, such as monocyte-
macrophage cells infiltration into the CNS (Ferrucci et al., 2013).
These HIV-1-induced symptoms affect disease progression
as well as HIV pathogenesis. Furthermore, pro-inflammatory
cytokines (IL 6 and 8), chemoattractants secretion levels,
caspase activity, migration inhibition factor and MCP-1 levels
were observed to increase in human fetal astrocytes. The
glycolytic pathway was also observed to decrease by damage of
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) activity,
which led to reduced ATP levels (Ferrucci et al., 2013). The
decrease in intracellular ATP will lead to an accumulation
of ROS, which reduces GSH concentrations that affect a
variety of genes in the Redox pathway. Additionally, SK-
N-SH neuroblastoma cell line exposed to Vpr conditioned
medium led to a reduction in GSH synthesis, resulting in
apoptosis of the cells. Therefore, these data also showed
how Vpr was able to ultimately disturb neuronal survival
and affect astrocytic metabolism that lead to the BBB
dysfunction (Ferrucci et al., 2013). In Figure 2, we have
illustrated effect of HIV-1 proteins on BBB integrity and
function.
Targeting Active and Latent HIV in the
Brain
The combination antiretroviral therapy (cART) and the available
antiretroviral drugs are effective only in decreasing the
viral load in the peripheral system but cannot eradicate
the active or latent (reservoir) in the brain. The BBB is
considered as a primary impediment barrier for the majority
of drugs used in the treatment of HIV. Therefore, delivering
antiretroviral drugs into the brain is still a big challenge
to date. Based on the physico-chemical characteristics and
the amount of drug concentration in the CNS, antiretroviral
drugs were classified into low-CNS penetration, intermediate
CNS penetration or high CNS penetration drugs (Letendre
et al., 2008). Nanoparticles and nano-carrier based delivery
of the anti-retroviral drugs across the BBB offer a great
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FIGURE 2 | Schematic representation showing effect of HIV proteins on BBB permeability and function.
promise for neurotherapeutics (Vyas et al., 2006; Boisselier and
Astruc, 2009; Nowacek and Gendelman, 2009; Mahajan et al.,
2012).
Nanotechnology Based Therapeutic
Approach to Deliver Drugs Across BBB to
Treat NeuroAIDS
Over the last few years, research studies have focused on
exploring different nano-carriers systems to deliver anti-retro
viral drugs to the brain (Wong et al., 2010; Sagar et al., 2014).
Our lab is extensively studying the use of nano carrier system
to deliver antiretroviral drugs and latency breaking agents into
the brain. We have reported that multifunctional liposomal
magnetic nanocarriers have an immense capacity for particle
transmigration through the BBB and may possess a promising
future in drug delivery to the brain (Saiyed et al., 2010; Pilakka-
Kanthikeel et al., 2013; Ding et al., 2014). Recently, we have
reported the use of sustain released magnetically guided layer-
by-layer (LbL) assembled nanocarriers for the treatment of
neuroAIDS. We have reported that the use of vorinostat and
tenofovir in a single nanoformulation is helpful for activating
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latent viruses and killing them simultaneously (Atluri et al., 2014;
Jayant et al., 2015).
Conclusion
HIV-associated neurocognitive disorders are becoming a
growing problem as the HIV-1-infected population ages. One of
the pathological hallmarks of HAND and dementia is the BBB
dysfunction that plays a critical role in this process. The BBB
is more than ordinary hurdles to the passage of molecules and
cells, and hence active players in brain homeostasis and its role
in HIV-1 infection and HAND are still to be further recognized
and investigated in the context of health and disease and in
neurocognitive disorders. In this review, we emphasized that the
communication between the periphery and the brain, through
the brain barriers, is compromised during HIV-1 infection.
Despite the well-accepted fact that the barriers are active
participants in brain homeostasis, further studies are required
to fully understand how the barriers function is altered during
HIV-1 infection, possible compromise and its contribution to
neurodegenerative diseases such as HAND and HIV associated
dementia.
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